Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Twist Bioscience (TWST) and raises the price target from $39 to $40.
May 03, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird maintains an Outperform rating on Twist Bioscience and raises the price target from $39 to $40.
The increase in price target by Baird reflects a positive outlook on Twist Bioscience, suggesting confidence in the company's future performance. This analyst endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100